Engraftment data
. | AML/ALL . | . | Lymphoma/myeloma . | . | ||
|---|---|---|---|---|---|---|
. | Median . | Range . | Median . | Range . | ||
| Day to ANC higher than 0.5 × 109/L* | 23‡ | 13-53 | 13 | 8-24 | ||
| Day to PLT higher than 20 × 109/L | 52‡ | 40-120 | 15 | 12-75 | ||
| Day to PLT higher than 50 × 109/L | 90‡ | 46-207 | 22 | 12-180 | ||
| Parenteral antibiotics, d | 11 | 7-25 | 7 | 4-32 | ||
| Days on G-CSF after ABMT† | 11 | 2-40 | 11 | 5-35 | ||
| Days to hospital discharge | 27‡ | 14-39 | 17 | 12-40 | ||
. | AML/ALL . | . | Lymphoma/myeloma . | . | ||
|---|---|---|---|---|---|---|
. | Median . | Range . | Median . | Range . | ||
| Day to ANC higher than 0.5 × 109/L* | 23‡ | 13-53 | 13 | 8-24 | ||
| Day to PLT higher than 20 × 109/L | 52‡ | 40-120 | 15 | 12-75 | ||
| Day to PLT higher than 50 × 109/L | 90‡ | 46-207 | 22 | 12-180 | ||
| Parenteral antibiotics, d | 11 | 7-25 | 7 | 4-32 | ||
| Days on G-CSF after ABMT† | 11 | 2-40 | 11 | 5-35 | ||
| Days to hospital discharge | 27‡ | 14-39 | 17 | 12-40 | ||
In the AML/ALL group, 57.1% of patients had documented infections, and 87.5% of patients received parenteral antibiotics. In the lymphoma/myeloma group, 23.1% of patients had documented infections, and 59.4% of patients received parenteral antibiotics (P < .05 for both comparisons).
ANC indicates absolute neutrophil count; PLT, platelet count; and ABMT, autologous bone marrow transplantation.
Of the patients, 6 are not evaluable for hematopoietic reconstitution and 2 are still platelet-transfusion dependent. For further details, see the “Results.”
All lymphoma/myeloma patients received 5 μg/kg per day of G-CSF starting at day +6 after autograft. Of 21 acute leukemia patients, 18 received G-CSF upon clinical indication.
P < .05.